Melanoma incidence has been rapidly increasing worldwide, with fewer than 10% of people whose melanoma tumours have spread or metastasized surviving longer than a decade after detection.  Despite the considerable progress that has been made in the clinical treatment of melanoma, reliable markers to predict treatment response or to measure early recurrent disease are still not available.  Now, a study from researchers at NYU Langone Medical … Continue reading New ctDNA blood-test for melanoma beats standardised test in human trials.